Heterogeneity of glioblastoma with gliomatosis cerebri growth pattern on diffusion and perfusion MRI
Background and purpose
Gliomatosis cerebri (GC) is a rare growth pattern of glioblastoma whose diffuse nature is reflected by unspecific, relatively uniform findings on conventional MRI. In the present study we sought to evaluate the additional value of diffusion (DWI) and perfusion weighted (PWI) MRI for a more detailed characterization.
We analyzed the MRI findings in patients with histologically proven glioblastoma with GC growth pattern with a specific emphasis on T2 lesion pattern, volume, relative apparent diffusion coefficient (rACD), and relative cerebral blood volume (rCBV) and compared these to age-/gender-matched patients with localized glioblastoma.
Overall, 16 patients (median age 59.5 years, 4 male) were included in the study. Of these, 8 patients had a glioblastoma with GC growth pattern, and 8 a classical localized growth pattern. While the median rADC (1.27 [IQR 1.12–1.41]) within the T2 lesion was significant lower in glioblastoma with GC growth pattern compared to localized glioblastoma (1.74 [IQR 1.45–1.96]; p = 0.003), the median T2 lesion volume and rCBV within the T2 lesion did not differ significantly. Furthermore, six patients with glioblastoma with GC growth pattern showed focal areas with significantly reduced rADC (p = 0.043), and/or increased rCBV (p = 0.028).
Lower rADC in glioblastoma with GC growth pattern might reflect the diffuse tumor cell infiltration whereas focal areas with decreased rADC and/or increased rCBV probably indicate high tumor cell density and/or abnormal tumor vessels which may be useful for biopsy guidance.
KeywordsGlioblastoma Gliomatosis cerebri Heterogeneity Diffusion-weighted imaging DWI Perfusion-weighted imaging PWI
Compliance with ethical standards
Conflict of interest
Alex Förster: none. Stefanie Brehmer received travel support from Carl Zeiss Meditec AG. Marcel Seiz-Rosenhagen: none. Iris Mildenberger: none. Frank A. Giordano serves as consultant and speaker for Carl Zeiss Meditec AG, NOXXON Pharma AG, Merck Serono GmbH, Roche Pharma AG, Siemens Healthcare Diagnostics GmbH, and holds patents related with Carl Zeiss Meditec AG. Holger Wenz: none. David Reuss: none. Daniel Hänggi: none. Christoph Groden: none.
This study has been approved by the local institutional review board (Medizinische Ethikkommission II der Medizinischen Fakultät Mannheim) and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Patient consent was waived for this analysis by the local institutional review board due to its retrospective nature.
- 1.Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMedGoogle Scholar
- 2.Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefPubMedGoogle Scholar
- 3.Scherer J (1940) The forms of growth in gliomas and their practical significance. Brain 40:631–635Google Scholar
- 9.Barajas RF Jr, Hodgson JG, Chang JS, Vandenberg SR, Yeh RF, Parsa AT, McDermott MW, Berger MS, Dillon WP, Cha S (2010) Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology 254(2):564–576CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Barajas RF Jr, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, Parsa AT, Aghi MK, McDermott MW, Berger MS, Cha S, Chang SM, Nelson SJ (2012) Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncology 14(7):942–954CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Constans JM, Collet S, Kauffmann F, Hossu G, Dou W, Ruan S, Rioult F, Derlon JM, Lechapt-Zalcmann E, Chapon F, Valable S, Theron J, Guillamo JS, Courtheoux P (2011) Five-year longitudinal MRI follow-up and (1)H single voxel MRS in 14 patients with gliomatosis treated with temodal, radiotherapy and antiangiogenic therapy. Neuroradiol J 24(3):401–414CrossRefPubMedGoogle Scholar
- 24.Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, Smith KA, Shapiro WR, Pinnaduwage DS, Coons SW, Nakaji P, Debbins J, Feuerstein BG, Baxter LC (2012) Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 33(1):69–76CrossRefPubMedGoogle Scholar
- 28.Tsougos I, Svolos P, Kousi E, Fountas K, Theodorou K, Fezoulidis I, Kapsalaki E (2012) Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3 T. Cancer Imaging 12:423–436CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Neska-Matuszewska M, Bladowska J, Sasiadek M, Zimny A (2018) Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-searching for a practical approach. PLoS ONE 13(1):e0191341CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Lehmann P, Saliou G, de Marco G, Monet P, Souraya SE, Bruniau A, Vallee JN, Ducreux D (2012) Cerebral peritumoral oedema study: does a single dynamic MR sequence assessing perfusion and permeability can help to differentiate glioblastoma from metastasis? Eur J Radiol 81(3):522–527CrossRefPubMedGoogle Scholar